Assessment of Oral CSF 1-Receptor Inhibition with PLX 3397 for Tenosynovial Giant Cell Tumor / Pigmented Villonodular Synovitis using Novel Modified RECIST , Tumor Volume Scoring , and Tissue Damage Scoring Methods

Charles Peterfy, MD, PhD, William D. Tap, MD, Julie DiCarlo, PhD, Zev A. Wainberg, MD, Chao Zhang, PhD, Arthur P. Staddon, MD, Allen Lee Cohn, MD, Geoffrey Shapiro, MD, PhD, Igor Puzanov, MD, Eunice L. Kwak, MD, PhD, Henry H. Hsu, MD, Paul S. Lin, MBA, MD, Sandra Tong, MD, John H. Healey, MD. Spire Sciences, Inc., Boca Raton, FL, USA, Memorial Sloan Kettering Cancer Center, New York, NY, USA, UCLA, Los Angeles,, CA, USA, Plexxikon Inc., Berkeley, CA, USA, University of Pennsylvania School of Medicine, Philadelphia, PA, USA, Rocky Mountain Cancer Center/US Oncology, Denver, CO, USA, DanaFarber Cancer Institute, Boston, MA, USA, Vanderbilt University Medical Center, Nashville, TN, USA.